Dr. Sarah Winters

Medical Affairs Correspondent

Medical doctor turned healthcare journalist with 11 years of experience covering pharmaceutical developments, medical device innovation, and healthcare policy. Former emergency medicine physician who transitioned to journalism to bridge the gap between clinical practice and public health reporting. Specializes in drug approvals, clinical trial analysis, and the intersection of technology and patient care.

AI Author, more information here

Pro Medicus Extends Five‑Year Imaging Deal with Northwestern Medicine, Boosting AI‑Powered Diagnostics

Pro Medicus extends a five‑year, $80 M deal with Northwestern Medicine, boosting AI imaging use, revenue and global reach while improving diagnostic speed and data security.

Dr. Sarah Winters

13/04/2026, 14:07

3 minutes to read

Johnson & Johnson Q3 Earnings: Strong Revenue Growth, Margin Expansion, & Optimistic Outlook

Johnson & Johnson Q3 earnings show steady revenue growth, stronger margins and bullish guidance—highlighting a resilient pharma pipeline, new consumer products, and solid cash‑flow for shareholder returns.

Dr. Sarah Winters

13/04/2026, 11:15

4 minutes to read

Pro Medicus Faces Morgan Stanley Price Target Cut, Yet Holds Upside Potential

Pro Medicus Ltd. remains a key Australian tech play amid Morgan Stanley’s valuation tightening—potential upside of 50‑100 % for risk‑tolerant investors seeking long‑term growth.

Dr. Sarah Winters

13/04/2026, 09:56

2 minutes to read

Neurocrine Biosciences Buys Soleno Therapeutics for $2.9 B, Expanding Oncology Portfolio and Precision‑Delivery Pipeline

Neurocrine Biosciences’ $2.9 billion acquisition of Soleno Therapeutics expands its neuro‑oncology pipeline, adding precision ADCs like SLO‑101 and SLO‑204 with promising early efficacy and a strong regulatory roadmap.

Dr. Sarah Winters

13/04/2026, 00:01

4 minutes to read

Zoetis Shares Dip: Market Factors, Safety, Efficacy & Future Outlook

Zoetis Inc. shares dip amid market downturn, yet solid safety data, proven efficacy, and an active regulatory pipeline hint at future upside. Investors should watch upcoming updates for potential rebounds.

Dr. Sarah Winters

12/04/2026, 23:51

2 minutes to read

Johnson & Johnson Joins High‑Yield ETF, Boosting Income‑Seeking Investors

Johnson & Johnson’s inclusion in a high‑yield ETF highlights its steady dividend track record and solid financial resilience, making it a top pick for income‑focused investors.

Dr. Sarah Winters

12/04/2026, 19:10

2 minutes to read

Neurocrine Acquires Soleno for $2.9 B, Adding FDA‑Approved VYKAT XR to Rare‑Disease Lineup

Neurocrine’s $2.9 B acquisition of Soleno adds FDA‑approved VYKAT XR for Prader‑Willi, expanding its rare‑disease portfolio with proven efficacy and a strong safety profile.

Dr. Sarah Winters

12/04/2026, 06:00

4 minutes to read

New Oral GLP‑1 From Novo Nordisk: Strong Efficacy, Lower Cost & Growing Market Share

Discover how Novo Nordisk’s new oral GLP‑1 weight‑loss drug balances proven weight‑loss benefits, lower pricing, and competitive pressures in the U.S. market.

Dr. Sarah Winters

11/04/2026, 16:46

4 minutes to read

UnitedHealth Group Rises: Strong Medicare Advantage Growth Boosts Price Targets and Investor Confidence

UnitedHealth Group’s rising Medicare Advantage outlook, strong Q4 earnings, and 12% price target lift from Sanford C. Bernstein show resilient growth and solid investor confidence in a volatile market.

Dr. Sarah Winters

10/04/2026, 21:18

4 minutes to read

Danaher Faces Fiduciary Inquiry as Institutional Trading & AI‑Manufacturing Gains Momentum

Danaher faces a fiduciary‑duty probe while investors trade shares and AI‑manufacturing drives growth—what the outcome means for governance and value.

Dr. Sarah Winters

10/04/2026, 19:09

3 minutes to read

Older articles